Mark Robert Litzow
Impact in
- Hematology top 0.01%
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Multiple Myeloma Research and Treatments
- Chronic Myeloid Leukemia Treatments
- Genetics top 0.1%
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
Papers in
- Hematology 572
- Acute Myeloid Leukemia Research 321
- Hematopoietic Stem Cell Transplantation 233
- Multiple Myeloma Research and Treatments 41
- Chronic Myeloid Leukemia Treatments 26
- Genetics 72
- Myeloproliferative Neoplasms: Diagnosis and Treatment 55
- Chronic Lymphocytic Leukemia Research 17
- Co-authors
- Ayalew Tefferi (152 shared papers)Martin S. Tallman (99 shared papers)William J. Hogan (239 shared papers)Hillard Michael Lazarus (80 shared papers)Jacob M. Rowe (48 shared papers)Selina M. Luger (66 shared papers)Elisabeth M. Paietta (70 shared papers)Morie Abraham Gertz (80 shared papers)
- Journals
- Blood (202 papers)Transplantation and Cellular Therapy (111 papers)American Journal of Hematology (47 papers)Bone Marrow Transplantation (45 papers)Blood Advances (44 papers)
- Partner nations
- United StatesIsraelUnited Kingdom
In The Last Decade
Mark Robert Litzow
834 papers receiving 39.4k citations
Mark Robert Litzow's Hit Papers
Peers
Comparison fields: 5 of 162
- Hematology 20.3k
- Genetics 4.9k
- Public Health, Environmental and Occupational Health 7k
- Oncology 2.8k
- Immunology 1.6k
Countries citing papers authored by Mark Robert Litzow
This map shows the geographic impact of Mark Robert Litzow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Robert Litzow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Robert Litzow more than expected).
Fields of papers citing papers by Mark Robert Litzow
This network shows the impact of papers produced by Mark Robert Litzow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Robert Litzow. The network helps show where Mark Robert Litzow may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Robert Litzow, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 870 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia Hit paper breakdown → | 2012 | 1634 |
| 2 | Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study Hit paper breakdown → | 2014 | 1076 |
| 3 | MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients Hit paper breakdown → | 2006 | 873 |
| 4 | Anthracycline Dose Intensification in Acute Myeloid Leukemia Hit paper breakdown → | 2009 | 770 |
| 5 | Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL Hit paper breakdown → | 2018 | 751 |
| 6 | International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium Hit paper breakdown → | 2015 | 719 |
| 7 | Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study Hit paper breakdown → | 2006 | 686 |
| 8 | In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993) Hit paper breakdown → | 2007 | 657 |
| 9 | Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial Hit paper breakdown → | 2006 | 616 |
| 10 | Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia Hit paper breakdown → | 2019 | 608 |
| 11 | Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance Hit paper breakdown → | 2007 | 604 |
| 12 | Risk factors for acute GVHD and survival after hematopoietic cell transplantation Hit paper breakdown → | 2011 | 557 |
| 13 | First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation Hit paper breakdown → | 2012 | 504 |
| 14 | 1998 | 479 | |
| 15 | PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia Hit paper breakdown → | 2019 | 463 |
| 16 | Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study Hit paper breakdown → | 2017 | 416 |
| 17 | A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403 Hit paper breakdown → | 2019 | 380 |
| 18 | 2010 | 370 | |
| 19 | High Frequency and Poor Outcome of Philadelphia Chromosome–Like Acute Lymphoblastic Leukemia in Adults Hit paper breakdown → | 2017 | 354 |
| 20 | 2000 | 351 |
About Mark Robert Litzow
Mark Robert Litzow is a scholar working on Hematology, Genetics, Public Health, Environmental and Occupational Health, Oncology and Immunology, having authored 870 papers that have together received 40.4k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (321 papers), Hematopoietic Stem Cell Transplantation (233 papers), Acute Lymphoblastic Leukemia research (146 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (55 papers), Multiple Myeloma Research and Treatments (41 papers), Chronic Myeloid Leukemia Treatments (26 papers), Chronic Lymphocytic Leukemia Research (17 papers) and Amyloidosis: Diagnosis, Treatment, Outcomes (16 papers). The work is most often cited by research in Hematology (20.3k citations), Genetics (4.9k citations), Public Health, Environmental and Occupational Health (7k citations), Oncology (2.8k citations) and Immunology (1.6k citations). Mark Robert Litzow has collaborated with scholars based in United States, Israel and United Kingdom. Frequent co-authors include Ayalew Tefferi, Martin S. Tallman, William J. Hogan, Hillard Michael Lazarus, Jacob M. Rowe, Selina M. Luger, Elisabeth M. Paietta, Morie Abraham Gertz, Martha Q. Lacy and Angela A. Dispenzieri. Their work appears in journals such as Blood, Transplantation and Cellular Therapy, American Journal of Hematology, Bone Marrow Transplantation and Blood Advances.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.